gadodiamide
Trade name: Omniscan
Small moleculeapproved
Approved
Jan 8, 1993
Gadodiamide is a nonionic, low-osmolar gadolinium-based contrast agent for diagnostic contrast-enhanced magnetic resonance imaging (MRI). — NCATS
Clinical trial activity
6 trials · 11 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
3
Earliest trial started Sep 1, 2003 (NCT00209391)
Timeline
1990s
- Jan 8, 1993
General Electric — Earliest FDA Approval
- Jan 8, 1993
General Electric — NDA Secondary Org
- Jan 8, 1993
General Electric — NDA Organization
2000s
- Jan 1, 2003
General Electric — Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Diagnostic agent
- UnclearUnclear
Unclear unclear
Approval history
- approvedJan 8, 1993
Chemistry & pharmacology
Loading structure…
SMILES
[Gd+3].CNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NC)CC([O-])=O)CC([O-])=O- Mol. weight
- 573.66 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Black box warning
Sources
- WikipediaGadodiamide ↗
- NCATS84F6U3J2R6 ↗
- ChEMBLCHEMBL1200346 ↗
Also known as
- amersham brand of gadodiamide
- gadodiamide
- gadodiamide
- gadodiamide
- gadodiamide
- gadodiamide
- gadodiamide
- gadodiamide
- gadodiamide
- gadodiamide anhydrous
- gadodiamide anhydrous
- gadolinium, aqua(5,8-bis(carboxymethyl)-11-(2-(methylamino)-2-oxoethyl)-3-oxo-2,5,8,11-tetraazatridecan-13-oato(3-))-, hydrate
- gd-dtpa bis-(methylamide)
- gd-dtpa-bma
- gddtpa-bma
- gddtpa-bma
- nycomed brand of gadodiamide
- omniscan
- omniscan
- omniscan
- omniscan
- omniscan
- omniscan
- omniscan
- omniscan unique softpack
- s-041
- s-041
- sanofi winthrop brand of gadodiamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04776187 | Phase 4 | Mar 1, 2021 | Hengrui Therapeutics, Inc., The Central Hospital of Lishui City |
| NCT04373564 | Phase 4 | Jul 1, 2020 | Bayer, Bracco, General Electric, Guerbet, IQVIA |
| NCT02501759 | N/A | May 1, 2015 | Medical Research Foundation, Oregon, National Cancer Institute (NCI), Oregon Health and Science University |
| NCT00908310 | Phase 4 | May 1, 2009 | General Electric, Optum |
| NCT00209443 | Phase 3 | Sep 1, 2004 | General Electric |
| NCT00209391 | Phase 3 | Sep 1, 2003 | General Electric |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| General Electric | For profit | 4 | 3 | 2 | 2003 |
| Bayer | For profit | 1 | 0 | 1 | 2020 |
| Bracco | For profit | 1 | 0 | 1 | 2020 |
| Guerbet | For profit | 1 | 1 | 1 | 2020 |
| Hengrui Therapeutics, Inc. | For profit | 1 | 0 | 1 | 2021 |
| IQVIA | For profit | 1 | 0 | 1 | 2020 |
| Medical Research Foundation, Oregon | Academic/Hospital | 1 | 0 | 1 | 2015 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2015 |
| Optum | For profit | 1 | 0 | 1 | 2009 |
| Oregon Health and Science University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| The Central Hospital of Lishui City | Academic/Hospital | 1 | 1 | 1 | 2021 |
11 organizations
Page 1 / 1
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| General Electric | For profit | NDA2 | Jan 8, 1993 |
| General Electric | For profit | NDA | Jan 8, 1993 |